Skip to main content

Table 1 Comparison of growth kinetics (doubling time) of RT112, RT112rGEMCI20, RT112luc, and RT112rGEMCI20luc cell lines and cell viability (IC50) after treatment with gemcitabine

From: Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

Cell line

Doubling time (h)

IC50 (ng/ml)

RT112

23.28 ± 2.88

1.63 ± 0.55

RT112rGEMCI20

25.2 ± 3.12

125.40 ± 29.78

RT112luc

24.72 ± 5.04

1.94 ± 0.24

RT112rGEMCI20luc

27.36 ± 3.6

114.39 ± 14.52